Nadezhda Y.
- Country
- Bulgaria
- Department
- Rheumatology
Research Overview
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Subcutaneous Ianalumab (VAY736) Added to Standard Therapy in Systemic Lupus Erythematosus
- Phase 3 Randomized Double-blind Placebo-controlled Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
- Efficacy and Safety Evaluation of Zasocitinib (TAK-279) Versus Apremilast and Placebo in Biologic-Naïve Adults with Active Psoriatic Arthritis
Data & Insights
Has run more than one trial at 41 of 197 partner sites.
Specializations
Systemic Autoimmune Disorders
The investigator concentrates on therapeutic strategies for Systemic Lupus Erythematosus, aiming to reduce disease activity and improve long‑term outcomes.
- Targeted S1P receptor modulation
- Anti‑interferon pathway inhibition
- Combination with standard lupus care
Research is conducted at Dkc 1 Ruse EOOD in Ruse, Bulgaria.
Cutaneous Lupus Therapy
Focused on skin‑limited disease, the work addresses Cutaneous Lupus Erythematosus in both subacute and chronic forms.
- Topical and systemic biologic agents
- Skin disease activity scoring systems
- Management of antimalarial‑refractory cases
Efforts aim to achieve durable skin clearance while maintaining safety.
Psoriatic Arthritis Innovation
In the realm of inflammatory arthritis, the investigator explores treatments for Psoriatic Arthritis that have not responded to conventional biologics.
- Dual IL‑17A/F inhibition
- JAK/STAT pathway targeting
- Patient‑reported outcome optimization
Studies aim to improve joint function and skin involvement simultaneously.
Targeted Breast Cancer Therapy
The investigator also contributes to oncology by focusing on Advanced ER‑positive/HER2‑negative Breast Cancer in patients with prior endocrine treatment.
- Selective estrogen receptor degraders
- Combination with endocrine agents
- Progression‑free survival endpoints
Research integrates endocrine resistance mechanisms with novel therapeutics.
Emerging Immunomodulatory Agents
Across multiple autoimmune indications, the investigator evaluates next‑generation immunomodulators such as BIIB059 and ianalumab.
- Anti‑type I interferon antibodies
- Fc‑engineered IgG therapeutics
- Long‑term safety monitoring
These agents are studied for their potential to modify disease pathways in lupus and related conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.